Laboratory Corp. of American Holdings (LH-N) Stock Predictions - Stockchase
WATCH LIST
3
Laboratory Corp. of American Holdings (LH-N)

ON STOCKCHASE SINCE Dec 2006

independent clinical laboratory company

biotechnology/pharmaceutical

Laboratory Corp. of Ameri...

LH-N

0 watching          
Join the Discussion

Laboratory Corp. of American Holdings (LH-N) SAVE Apr, 25, 2019, 1:44 am

153.96 2.67 (1.76%)

About Laboratory Corp. of American Holdings (LH-N)

Laboratory Corporation of America Holdings, more commonly known as LabCorp, is an American S&P 500 company headquartered in Burlington, North Carolina. More at Wikipedia

What the experts are saying about LH-N



  • All
  • Filtered
Signal Opinion Expert
TOP PICK

Clinical research and testing for drug companies.  They have really good visibility of growth ahead of it.  (Analysts’ target: $155.00).

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Clinical research and testing for drug companies.  They have really good visibility of growth ahead of it.  (Analysts’ target: $155.00).

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Andy Nasr

VP & Inves, Sentry Investments...

Price Price
$143.470
Owned Owned
Yes

TOP PICK
Clinical labs. 2 big players own most of the market. Expects volume will increase because of aging population needing more and more tests. Very profitable.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Clinical labs. 2 big players own most of the market. Expects volume will increase because of aging population needing more and more tests. Very profitable.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Brad Willock

Vice Presi, RBC Asset Management...

Price Price
$71.730
Owned Owned
Yes

TOP PICK
Clinical testing lab. About 40% of US tests by doctors go to either this or Quest Diagnostics (DGX-N). With an aging population, there is more testing giving more revenue. Very predictable, high cash flow driven model.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Clinical testing lab. About 40% of US tests by doctors go to either this or Quest Diagnostics (DGX-N). With an aging population, there is more testing giving more revenue. Very predictable, high cash flow driven model.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Brad Willock

Vice Presi, RBC Asset Management...

Price Price
$72.380
Owned Owned
Yes

Showing 1 to 3 of 3 entries
Successfully Saved Company
Successfully Saved Company
1+
JOIN THE DISCUSSION
1 comments in the last 7 days